A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors
An Open-label Phase I/II, Dose Escalation, Dose Optimization, and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity, and Antitumor Activity of IPN60350 as Monotherapy or in Combination With Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety of a new medicine called IPN60350 and how the body responds to it. Researchers will also look for early signs of antitumor activity in adults with locally advanced or metastatic solid tumors.
All participants in this study will receive IPN60350, either alone or in combination with other anticancer therapies.
The study has two parts.
- Phase Ia (dose escalation) will test IPN60350 at different dose levels to learn which doses are safe and can be given in future parts of the study.
- Phase Ib (dose optimization and expansion) will test one or more selected dose levels in a larger number of participants. This will help researchers better understand the safety of IPN60350 and whether it shows early signs of antitumor activity in different tumor types.
Each part will consist of the following periods:
- A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study center.
- A treatment period where IPN60350 is administered in repeating treatment cycles.
The study includes health assessments, blood tests, tissue samples (biopsies), and imaging scans to help researchers better understand the safety of IPN60350 and its potential effects on tumors.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Ipsen Clinical Study Enquiries
- 电话号码:See email
- 邮箱:clinical.trials@ipsen.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Participant must be ≥18 years of age, at the time of signing the informed consent.
-
Histologically or cytologically confirmed locally advanced/metastatic solid tumors.
-
Have at least 1 measurable disease per RECIST version 1.1.
-
Participants with solid tumors who have:
- Relapsed or refractory disease after receiving at least 1 prior therapy known to provide clinical benefit for their disease based on locally approved standard of care; AND
- No remaining available approved therapy; or for whom locally approved standard therapies are contraindicated or not deemed appropriate by the treating investigator.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
-
Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
-
Left ventricular ejection fraction (LVEF) >50%.
-
Adequate bone marrow function.
-
Adequate hepatic function and absence of laboratory abnormalities indicating hepatic injury before first dose of study intervention.
-
Adequate renal function before first dose of study intervention.
-
Prothrombin time (PT) or international normalized ratio (INR) ≤1.5× upper limit of normal (ULN).
-
At the time of screening, a tumor tissue specimen is required for enrollment into phase Ia and phase Ib parts of the study.
Exclusion Criteria:
- Known second malignancy either progressing or requiring active treatment.
- Has not recovered (i.e., to CTCAE version 6.0 Grade 1 or to baseline) from previous anticancer therapy-induced AEs. Note: Grade ≤2 AEs with no impact on participant safety are exceptions to this criterion and may qualify for the study, e.g., Grade ≤2 hair loss or stable peripheral neuropathy.
- Major surgery before receiving the first dose of study treatment. Participants must have adequate wound healing and have recovered from surgery related complications/toxicities prior to first dose.
- Active brain metastases or leptomeningeal metastases.
- Significant concurrent, uncontrolled medical condition that would put participants at unacceptable risk from study participation or preclude them from complying with study procedures as per investigator assessment, including, but not limited to renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging screening.
- Clinically significant pulmonary disease that may increase the risk of drug-related pneumonitis, including but not limited to pulmonary fibrosis, severe or uncontrolled chronic obstructive pulmonary disease (COPD), uncontrolled asthma, or ongoing pulmonary infection.
- Participants with uncontrolled human immunodeficiency virus (HIV). HIV-infected participants are eligible if they meet criteria specified in protocol.
- Known active infection with hepatitis B virus (HBV) OR hepatitis C virus (HCV). Participants are eligible if they meet criteria described in the protocol.
- History of allogeneic organ transplantation or graft-versus-host disease.
- Known hypersensitivity to study drug, other monoclonal antibodies, or any of the excipients including sensitivity to heparin or heparin-induced thrombocytopenia.
- Clinically significant cardiovascular or cerebrovascular disease including but not limited to acute myocardial infarction, unstable or severe angina pectoris, endoscopic or open-heart cardiac surgery, stroke, transient ischemic attack, cerebral hemorrhage, or cerebral infarction, congestive heart failure, arrhythmia, or uncontrolled hypertension.
Note: Additional protocol specified inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Phase Ia: Dose Escalation
Participants will receive IPN60350, at the assigned dose level. |
IPN60350 will be administered at the assigned dose level. |
|
实验性的:Phase Ib: Dose Optimization and Expansion
At dose optimization, participants will be randomized to receive IPN60350, at one of the two doses of interest. |
IPN60350 will be administered at the assigned dose level. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase Ia: Percentage of Participants With Dose Limiting Toxicities (DLTs)
大体时间:Up to Day 21 following study drug administration
|
Up to Day 21 following study drug administration
|
|
|
Phase Ia and Ib: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
大体时间:From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
|
An adverse event (AE) is any unfavorable medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A TEAE is defined as an AE with onset from the first dose of study intervention, until the safety follow-up visit, or prior to the start of a new anticancer treatment, whichever is earlier. TEAEs and TESAEs will be graded using National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI CTCAE) version 6.0. |
From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
|
|
Phase Ib: Objective Response Rate (ORR)
大体时间:From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR), as determined by investigator per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). |
From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
|
Phase Ib: Percentage of Participants With Dose Interruptions and Permanent Treatment Discontinuations
大体时间:From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
|
From the first IPN60350 administration until 30 days after last dose (up to approximately 3.5 years)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase Ia: Time to Maximum Observed Drug Concentration (Tmax) of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: Maximum Observed Drug Concentration (Cmax) of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: Area Under the Plasma Concentration Time Curve Over a Dosing Interval (AUCtau) of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: Tmax of Total Antibody (Tab) of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: Cmax of Tab of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: AUCtau of Tab of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: Tmax of Free Toxin of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: Cmax of Free Toxin of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia: AUCtau of Free Toxin of IPN60350
大体时间:Within 21 days following drug administration
|
Within 21 days following drug administration
|
|
|
Phase Ia and Ib: Percentage of Participants With Treatment-Emergent Anti-drug Antibodies (ADA), Including Binding and Neutralizing Antibodies.
大体时间:From pre-dose on Day 1 up to end of study (up to approximately 3.5 years)
|
From pre-dose on Day 1 up to end of study (up to approximately 3.5 years)
|
|
|
Phase Ia: Objective Response Rate (ORR)
大体时间:From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
ORR is defined as the percentage of participants with BOR of CR or PR, as determined by investigator per RECIST version 1.1. |
From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
|
Phase Ib: Duration of Response (DoR)
大体时间:From first confirmed documented response (CR or PR) to the earliest date of documented disease progression, new anticancer therapy or death due to any cause (up to approximately 3.5 years)
|
DoR is defined as the time from the first documented evidence of CR or PR until progressive disease, as determined by investigator per RECIST version 1.1, or death from any cause, whichever occurs first. |
From first confirmed documented response (CR or PR) to the earliest date of documented disease progression, new anticancer therapy or death due to any cause (up to approximately 3.5 years)
|
|
Phase Ib: Progression-free Survival (PFS)
大体时间:From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
PFS is defined as the time from the date of first IPN60350 administration to the date of the first documented disease progression, as determined by investigator per RECIST version 1.1, or death due to any cause, whichever occurs first. |
From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
|
Phase Ib: Disease Control Rate (DCR)
大体时间:From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
DCR is defined as the percentage of participants with BOR of CR, PR or stable disease (SD), as determined by investigator per RECIST version 1.1 |
From the first IPN60350 administration to the earliest date of documented disease progression, new anticancer therapy or death (up to approximately 3.5 years)
|
合作者和调查者
赞助
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CLIN-60350-450
- 2026-527553-18-00 (克蒂斯)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.
Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.
IPD 共享时间框架
Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.
IPD 共享访问标准
Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.